Denosumab-Related Osteonecrosis of the Jaw: A Case Report and Management Based on Pharmacokinetics  

Oleh:

Tae Min You ; Kang-Hee Lee ; Soo-Hyeon Lee ; Park, Wonse

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology (keterangan: ada di ClinicalKey) vol. 120 no. 05 (Nov. 2015), page 548–553.
Topik: Pharmacokinetics

Ketersediaan

Perpustakaan FK Nomor Panggil: O04.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Denosumab, a monoclonal antibody against the receptor activator for nuclear factor–kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts. Osteonecrosis of the jaw (ONJ) is a well-known, if rare, side effect of bisphosphonate therapy; however, cases of ONJ have also been reported since 2010 in patients taking denosumab. We describe here a patient who developed ONJ while receiving denosumab; the pharmacokinetics of denosumab and bisphosphonates are discussed in the context of ONJ management.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali